Vericel Corporation

Vericel Corporation, a for-profit manufacturer of advanced cell therapy and tissue engineering products headquartered in Cambridge, Massachusetts, operates as a prime contractor supplying surgical implants, cultured chondrocyte implants, and enzymatic debridement products to federal healthcare agencies on full-and-open competition with no set-aside designations across its entire 95-award footprint.

Vericel's federal capability set centers on orthopedic and reconstructive medical devices and biologics. The company's core product portfolio includes MACI (matrix-induced autologous chondrocyte implantation) cultured chondrocyte implants and surgical membranes for cartilage repair, PROS prosthetic knee implants for cartilage defect treatment, and cell-based tissue engineering solutions. The vendor's largest federal award is a $191.8 million cost-plus-fixed-fee definitive contract with the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR/BARDA), awarded April 1, 2026, running through March 31, 2036, for non-surgical enzymatic debridement products to maintain a vendor-managed inventory for national emergency preparedness and mass casualty response. This award represents a substantial expansion beyond Vericel's historical VA focus into federal emergency preparedness. Representative smaller awards include purchase orders from the Department of Veterans Affairs' Veterans Integrated Service Networks for MACI final product assembled with membrane ($76,400, VISN 1, September 2026); PROS knee cartilage defects treatment ($69,772, VISN 19, April 2026); and surgical implants ($152,800, VISN 6, July 2026), all on firm fixed-price terms with performance in Cambridge.

Customer concentration is bifurcated by dollar magnitude. By award count, 75% of the 95-award portfolio clusters within the Department of Veterans Affairs' regional networks: VISN 6 leads with 30 awards worth $1.5 million combined, followed by VISN 12 (12 awards, $596 thousand) and the Department of the Army Medical Command (12 awards, $1.2 million). By potential value, the BARDA contract dominates—99% of combined potential value ($197.1 million) flows to that single award, leaving the VA base as a residual but consistent revenue stream of approximately $5 million across 70-plus smaller purchase orders. This represents a significant strategic pivot from a vendor historically anchored to VA supply relationships toward federal emergency response infrastructure.

Vericel's award activity has been cyclical but recently energized. The past five years show 9 awards in 2022, declining to 4 in 2025, then rising to 8 in 2026. The recompete cliff is minimal: only 3 awards with completion dates in the next twenty-four months carry a combined potential value of $229 thousand, indicating limited near-term renewal risk. The vendor's category concentration is narrow—65 of 95 awards fall under Surgical Appliance and Supplies Manufacturing (NAICS 339113), with Medical And Surgical Instruments, Equipment, And Supplies dominating the PSC taxonomy at 84 awards. Vericel operates exclusively as a prime contractor; zero sub-award activity appears in the source data. The vendor does not sit on GWACs, IDIQs, or government-wide BPAs; all work is awarded directly as purchase orders or definitive contracts from federal agencies themselves.